Financial Comparison: MiNK Therapeutics (NASDAQ:INKT) and Achilles Therapeutics (NASDAQ:ACHL)

Achilles Therapeutics (NASDAQ:ACHL) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Institutional and Insider Ownership

56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by company insiders. Comparatively, 20.6% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Achilles Therapeutics and MiNK Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Achilles Therapeutics	N/A	-54.45%	-47.68%
MiNK Therapeutics	N/A	N/A	-189.14%

Valuation and Earnings

This table compares Achilles Therapeutics and MiNK Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achilles Therapeutics	N/A	N/A	-$69.67 million	($1.65)	-0.84
MiNK Therapeutics	N/A	N/A	-$22.46 million	($3.90)	-2.85

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Achilles Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Achilles Therapeutics and MiNK Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achilles Therapeutics	0	1	1	0	2.50
MiNK Therapeutics	0	0	2	0	3.00

Achilles Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 188.81%. MiNK Therapeutics has a consensus price target of $65.00, indicating a potential upside of 484.53%. Given MiNK Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than Achilles Therapeutics.

Summary

MiNK Therapeutics beats Achilles Therapeutics on 6 of the 11 factors compared between the two stocks.

About Achilles Therapeutics

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.